Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stereotactic radiosurgery yields higher overall survival in patients with RCC metastatic to the brain

Haque W et al. Clinical Genitourinary Cancer 3 April 2018

Key clinical point: Treatment with stereotactic radiosurgery was superior to non-stereotactic radiotherapy for overall survival in patients with renal cell carcinoma metastatic to the brain.

Major finding: Higher overall survival was observed in the stereotactic radiosurgery cohort both before and following propensity matching. On subset analysis, differences persisted when stratifying for nephrectomy (p<0.001 for all). Treatment at an academic center independently predicted a higher rate of overall survival.

Study details: Data for 2005-2014 in the National Cancer Data Base for metastatic RCC and delivery of intracranial radiotherapy found 2,312 patients, 813 (35%) of whom received SRS and 1,499 of whom received non-SRS radiotherapy. Use of SRS increased from 27% in 2005 to 44% in 2014, and was less often given to low income and uninsured/Medicaid patients (p<0.05).

Disclosures: The researchers had no relevant financial disclosures.

Source: Haque W et al. Clinical Genitourinary Cancer 3 April 2018


Haque W et al. Clinical Genitourinary Cancer 3 April 2018

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours,

Must Reads in Renal Cell Carcinoma

EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4.

Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018.

Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.

Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.